European Society for Medical Oncology

IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer

Saturday, September 18, 2021 - 4:30pm

Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.

Key Points: 
  • Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.
  • IMFINZI plus chemotherapy continued to demonstrate a well-tolerated safety profile consistent with the known profiles of these medicines.
  • Results showed 32.5% of patients experienced a serious adverse event (all causality) with IMFINZI plus chemotherapy versus 36.5% with chemotherapy alone.
  • In June 2019, AstraZeneca announced the CASPIAN Phase III trial had met one primary endpoint of demonstrating OS for IMFINZI plus chemotherapy at a planned interim analysis.

IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer

Saturday, September 18, 2021 - 4:30pm

Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.

Key Points: 
  • Susan Galbraith, Executive Vice President, Oncology R&D, said: This remarkable improvement in survival is an unprecedented achievement at three years for patients with extensive-stage small cell lung cancer.
  • IMFINZI plus chemotherapy continued to demonstrate a well-tolerated safety profile consistent with the known profiles of these medicines.
  • Results showed 32.5% of patients experienced a serious adverse event (all causality) with IMFINZI plus chemotherapy versus 36.5% with chemotherapy alone.
  • In June 2019, AstraZeneca announced the CASPIAN Phase III trial had met one primary endpoint of demonstrating OS for IMFINZI plus chemotherapy at a planned interim analysis.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

Saturday, September 18, 2021 - 2:05pm

These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.

Key Points: 
  • These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.
  • Cervical cancer is the fourth most commonly diagnosed cancer in women and the fourth leading cause of cancer-related death in women globally.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021

Saturday, September 18, 2021 - 1:45pm

This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily.

Key Points: 
  • This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily.
  • There currently is no specific approved treatment for NSCLC patients with HER2 exon 20 insertion mutations.
  • Cohort 4 of the ZENITH20 clinical trial is enrolling treatment-nave NSCLC patients with HER2 exon 20 insertion mutations.
  • Poziotinib demonstrated clinically meaningful anti-tumor activity in newly diagnosed NSCLC patients with HER2 exon 20 mutations with 16mg QD dosing.

Epic Sciences Comprehensive Cancer Profiling Platform Shows Compelling Value Of Cell Analysis In Data Presented At ESMO Congress 2021

Saturday, September 18, 2021 - 12:59pm

SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic Sciences , Inc.'s (Epic) Comprehensive Cancer ProfilingPlatform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate.

Key Points: 
  • SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic Sciences , Inc.'s (Epic) Comprehensive Cancer ProfilingPlatform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate.
  • "Biomarker analysis is ongoing in this and other studies comparing the Epic Sciences PSMA CTC Assay with PSMA and FDG PET imaging, and patient outcomes.
  • The company's Comprehensive Cancer Profiling Platform, leverages proven and proprietary CTC capabilities, and adds ctDNA and immune cell analysis, to provide more complete data for more efficient analysis and clearer insights.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Saturday, September 18, 2021 - 5:30am

Grade 3/4 TEAEs occurred in 62% of patients who received Cabometyx vs. 28% for placebo, with no treatment-related grade 5 events.

Key Points: 
  • Grade 3/4 TEAEs occurred in 62% of patients who received Cabometyx vs. 28% for placebo, with no treatment-related grade 5 events.
  • For people living with advanced metastatic castration-resistant prostate cancer, the prognosis is often poor and the potential of new innovative therapies is critically important.
  • Additional endpoints include safety, overall survival and quality of life.2 More information about this trial is available at ClinicalTrials.gov .
  • A total of 651 patients (23% favorable risk, 58% intermediate risk, 20% poor risk; 25% PD-L1 1%) were randomized to Cabometyx plus Opdivo (n = 323) versus sunitinib (n = 328).

Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

Friday, September 17, 2021 - 12:45pm

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

Key Points: 
  • MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.
  • To read more about the Phase 2 COAST results, please see AstraZenecas press release here .
  • Were pleased to see the monalizumab COAST results, particularly the improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors

Friday, September 17, 2021 - 12:30pm

15 of the 16 patients evaluable for efficacy experienced regression of their target lesions, ranging in magnitude from 5% to 75%.

Key Points: 
  • 15 of the 16 patients evaluable for efficacy experienced regression of their target lesions, ranging in magnitude from 5% to 75%.
  • One patient with cholangiocarcinoma was also considered to have achieved a PR by investigator assessment, for an ORR of 31%.
  • Patients with treatment refractory cancer have very limited treatment options and will often need hospice and supportive care.
  • Our ambition with gavo-cel from the start was to redefine treatment for solid tumors with cell therapies.

IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer

Friday, September 17, 2021 - 12:30pm

The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.

Key Points: 
  • The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.
  • IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
  • Sequential vs Concurrent Chemoradiation for Stage III NonSmall Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.
  • Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What is New?

DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

Friday, September 17, 2021 - 12:30pm

New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.

Key Points: 
  • New first-in-human data from DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) being developed in strategic collaboration between Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute, showed promising early clinical activity in patients with several types of advanced solid tumors.
  • DS-7300 was tolerated across all dose levels (0.8 mg/kg -16.0 mg/kg) with no dose-limiting toxicities observed in 70 patients enrolled.
  • Stable disease has been reported in an additional 32 patients including 24 patients who are still being treated with various doses of DS-7300 as of data cut-off of July 21, 2021.
  • Patients enrolled in the dose escalation study received a median of four prior lines of therapy (range, 1-10).